References
- Williams D. B., Windebank A. J. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991; 66: 54–82
- Victor M., Ropper H. A. Degenerative diseases of the nervous system. Adams and Victor's Principles of Neurology. 7th edn. McGraw Hill, New York 2001; 1153–8
- Desnuelle C., Dib M., Garrel C., Favier A. A double‐blind, placebo‐controlled randomized clinical trial of alpha‐tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole‐tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 9–18
- Norris F., Shepherd R., Denys E., Mukai E., Elias L., Holden D., et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48–55
- Ackerman S. J., Sullivan E. M., Beusterien K. M., Natter H., Gelinas D. F., Patrick D. L. Cost effectiveness of recombinant human insulin‐like growth factor I therapy in patients with ALS. Pharmacoeconomics 1999; 15: 179–95
- Tavakoli M., Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci 2001; 191: 95–102
- Russell L. B., Gold M. R., Siegel J. E., Daniels N., Weinstein M. C. The role of cost‐effectiveness analysis in health and medicine. JAMA 1996; 276: 1172–7
- Torrance G. W., Boyle M. H., Horwood S. P. Application of multi‐attribute utility theory to measure social preferences for health states. Oper Res 1982; 30: 1043–69
- Torrance G. W., Furlong W., Feeny D., Boyle M. Multi‐attribute preference functions: health utilities index. Pharmacoeconomics 1995; 7: 503–20
- Cedarbaum J. M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999; 169: 13–21
- Feeny D., Furlong W., Torrance G. W., Goldsmith C., Zhu Z., DePauw S., et al. Multiattribute and single‐attribute utility functions for the health utilities index mark 3 system. Med Care 2002; 40: 113–28
- Torrance G. W. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1–30
- Patrick D. L., Starks H. E., Cain K. C., Uhlmann R. F., Pearlman R. A. Measuring preferences for health states worse than death. Med Decis Making 1994; 14: 9–18
- Torrance G. W., Feeny D. H., Furlong W. J., Barr R. D., Zhang Y., Wang Q. Multi‐attribute preference functions for a comprehensive health status classification system: health utilities index mark 2. Med Care 1996; 34: 702–22
- Kiebert G. M., Green C., Murphy C., Mitchell J. D., O'Brien M., Burrell A., et al. Patients' health‐related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 87–95
- Torrance G. W. Utility approach to measuring health‐related quality of life. J Chronic Dis 1987; 40: 593–600
- Grootendorst P., Feeny D., Furlong W. Health utilities index mark 3: evidence of construct validity for stroke and arthritis in a population health survey. Med Care 2000; 38: 290–9
- Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med 2001; 33: 344–9
- Chang W. T., Collins E. D., Kerrigan C. L. An internet‐based utility assessment of breast hypertrophy. Plast Reconstr Surg 2001; 108: 370–7